Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

SHR-A1811 Monotherapy Generates Similar pCR Rate as PCbHP in HER2+ Breast Cancer

August 14th 2025

The antibody-drug conjugate SHR-A1811 demonstrated a comparable pCR rate to SHR-A1811/pyrotinib and PCbHP in HER2-positive breast cancer.

FDA Grants Fast Track Designation to HLD-0915 for Metastatic Castration-Resistant Prostate Cancer

August 14th 2025

HLD-0915 has received fast track designation from the FDA, allowing for more frequent communication with the agency regarding the drug’s candidacy for approval.

Dr Somaiah on Mutation-Specific Therapy in Gastrointestinal Stromal Tumors

August 13th 2025

Neeta Somaiah, MD, discusses the landscape of mutation-specific therapy for the treatment of patients with a gastrointestinal stromal tumor.

Phase 3 Evaluation of Sigvotatug Vedotin Is Underway in Pretreated Nonsquamous NSCLC

August 13th 2025

Sigvotatug vedotin is being compared with docetaxel in patients with pretreated NSCLC in the phase 3 Be6A Lung-01 study.

CD19 t-haNK Leads to Complete Responses in Waldenstrom Macroglobulinemia

August 13th 2025

CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.

Health Canada Authorizes Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC

August 13th 2025

Perioperative pembrolizumab has received the green light for use in combination with radiotherapy with or without cisplatin in PD-L1–positive HNSCC.

Fulzerasib Displays Efficacy and Tolerability in KRAS G12C–Mutated Metastatic CRC

August 11th 2025

Fulzerasib monotherapy was safe and active in KRAS G12C–mutated metastatic colorectal cancer.

Dr Sanborn on Early Efficacy and Safety Data With Sigvotatug Vedotin Plus Pembrolizumab in NSCLC

August 8th 2025

Rachel E. Sanborn, MD, discusses preclinical and early clinical data supporting the use of the IB6-directed ADC sigvotatug vedotin in patients with NSCLC.

FDA Approval of Mirdametinib Reduces Treatment Barriers for Adult Patients With NF1-Associated PNs

August 7th 2025

Timothy Gershon, MD, PhD, discusses how the FDA approval of mirdametinib will affect the treatment paradigm for adult patients with NF1-associated PNs.

ASCO Updates Living Guidelines to Include New Treatment Strategies for NSCLC With/Without Driver Alterations

August 7th 2025

ASCO updated their clinical practice guidelines for stage IV NSCLC with or without a driver alteration.

NCCN Adds LEMS Antibody Testing, Treatment Recommendations to Clinical Practice Guidelines in SCLC

August 7th 2025

The NCCN Clinical Practice Guidelines in Oncology for SCLC added new recommendations for LEMS, the use of amifampridine, and VGCC antibody testing.

Novel ADC Sigvotatug Vedotin Generates Early Efficacy in NSCLC

August 7th 2025

Rachel E. Sanborn, MD, discusses the novel IB6-directed ADC sigvotatug vedotin for the treatment of patients with NSCLC.

FDA Grants Priority Review to Liso-Cel for R/R Marginal Zone Lymphoma

August 4th 2025

The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

Dr George on the Clinical Relevance of Targetable Mutations in GIST

August 4th 2025

Suzanne George, MD, discusses the evolving development of targeted therapies for patients with gastrointestinal stromal tumor.

Casdatifan Plus Cabozantinib Shows Early-Phase Efficacy in Clear Cell RCC

August 4th 2025

Rana R. McKay, MD, FASCO, discusses findings from the ARC-20 trial of casdatifan plus cabozantinib in pretreated clear cell renal cell carcinoma.

EMA Grants Orphan Drug Designation to Nuvisertib for Myelofibrosis

August 2nd 2025

Nuvisertib has received orphan drug designation from the EMA for patients with myelofibrosis.

China’s NMPA Accepts sNDA for Ivonescimab Plus Chemotherapy in Frontline Advanced Squamous NSCLC

July 31st 2025

Ivonescimab plus chemotherapy is under review in China for the frontline treatment of patients with advanced squamous non–small cell lung cancer.

First-Line Onvansertib Plus Bevacizumab and Chemo Yields Responses in RAS-Mutated mCRC

July 30th 2025

Onvansertib plus SOC generated responses with a tolerable safety profile in patients with previously untreated RAS-mutated metastatic colorectal cancer.

Namodenoson Surpasses Halfway Enrollment Benchmark in Advanced Pancreatic Cancer Trial

July 30th 2025

Can-Fite has reached the over 50% enrollment milestone for an ongoing phase 2a trial evaluating namodenoson in pancreatic cancer.

Knowledge of Unique ADC-Related Toxicities Is Critical for Safe, Effective Use in NSCLC

July 28th 2025

Corey J. Langer, MD, FACP, provides a focused overview of antibody-drug conjugate–related toxicities and AE management in lung cancer.